Product Information
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG is a generic product labeled by Teva Pharmaceuticals USA Inc., priced at $1.0341 per EA under NDC 00093500256. Its NADAC has been published 501 times since Jan 18, 2017.
FDA first approved this application on Nov 3, 2016. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG
Olmesartan Medoxomil, Amlodipine and HydrochlorothiazideStrength
10; 25; 40 mg/1; mg/1; mg/1
Manufacturer
Teva Pharmaceuticals USA Inc.NDC
00093500256
Classification
Generic
Dosage Form
TABLET, FILM COATED
Route
ORAL
Effective Date
8/19/2026
Active Ingredients
AMLODIPINE BESYLATE; HYDROCHLOROTHIAZIDE; OLMESARTAN MEDOXOMILApproval Type
Generic (ANDA)
FDA Application
ANDA202491FDA Approved
11/3/2016
TE Code
AB
On Market Since
11/14/2016
Pharmacological Classes
Price Statistics
The NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has been published 501 times since Jan 18, 2017, and over the history we have for it it has declined 70.9%. The table below summarizes its recorded NADAC range and movement.
| Current price | $1.0341 per EA |
|---|---|
| All-time high | $3.5502 (Feb 15, 2017) |
| All-time low | $1.0341 (Aug 19, 2026) |
| 52-week high | $1.3916 |
| 52-week low | $1.0341 |
| Median price | $1.7465 |
| Average price | $1.8926 |
| Largest weekly change | +29.2% (Dec 23, 2020) |
| Weeks tracked | 501 |
| Tracking since | Jan 18, 2017 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the Olmesartan Medoxomil, Amlodipine and Hydrochlorothiazide market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Frequently asked questions
What is the NADAC price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
The current National Average Drug Acquisition Cost (NADAC) for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG, manufactured by Teva Pharmaceuticals USA Inc., is $1.0341 per EA (NDC 00093500256), effective Aug 19, 2026.
How has the price of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG changed over time?
Over the history we have for it, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has declined 70.9%. It has been tracked across 501 weekly CMS publications since Jan 18, 2017.
What are the highest and lowest recorded NADAC prices for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
Since Jan 18, 2017, the NADAC for OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG has ranged from a low of $1.0341 (Aug 19, 2026) to a high of $3.5502 (Feb 15, 2017), with a median of $1.7465 per EA.
Are there cheaper alternatives to OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
No other NADAC-published product currently shares the active ingredient and strength of OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG?
OLMSRTN-AMLDPN-HYDROCHLOROTHIAZIDE 40-10-25 MG (NDC 00093500256) is labeled by Teva Pharmaceuticals USA Inc., and CMS classifies it as a generic product.